Jeremy Graff

Jeremy Graff is a seasoned executive with extensive experience in the pharmaceutical industry, currently serving as Senior Vice President and Global Head of Rare Disease Franchise at Biogen since February 2020, overseeing critical therapeutic areas including SMA and ALS, and managing a diverse portfolio of products such as SPINRAZA and QALSODY. Prior roles at Biogen include Senior Vice President of the Neuromuscular Disease Franchise and Vice President of Global Product Development and Commercialization for SPINRAZA. Previously, Graff held senior positions at Scipher Medicine and Horizon, where notable achievements included revitalizing the KRYSTEXXA brand, significantly increasing sales revenues. Early career experiences include leadership roles at AbbVie and Abbott, contributing to the successful market establishment of HUMIRA and the Women's Health portfolio. Graff holds a Bachelor of Science in Engineering from Cornell University and an MBA from The University of Chicago Booth School of Business.